Open AccessSurvival Rate of Metastatic Bone Disease Patients in Haji Adam Malik Hospital Medan
Author(s) -
Heru Hermantrie,
Pranajaya Dharma Kadar,
Andriandi,
Aznan Lelo
Publication year - 2019
Publication title -
international journal of pharmtech research
Language(s) - English
Resource type - Journals
eISSN - 2455-9563
pISSN - 0974-4304
DOI - 10.20902/ijptr.2019.120411
Subject(s) - medicine , survival rate , metastatic breast cancer , breast cancer , surgery , chemotherapy , 5 year survival rate , disease , retrospective cohort study , cancer
Objective -The aim of this study was to determining the survival rate of patient withmetastatic bone disease in Haji Adam Malik Hospital Medan. Material and Methods-The aim of thisretrospective study is to determine the survival rate of metastatic bone disease patients. Fifty-fivepatients who diagnosed of metastatic bone disease during January 2012 – December 2017 wereentered the inclusion criteria were ask and demographic data were also recorded to evaluate furtherassociated with primary lesion, and surviving status. Survival rate was assessed by Kapplan – MeierCurve. Results- From January 2012 to December 2017, a total 55 metastatic bone disease patientswere aged 43-77 years. Breast cancer (40%) was the most common primary cancer, with the lowestsurvival rate in cervic (10 months). Overall, patients who treat surgically and chemotherapy havesurvival rate 17 months. Conclusion-This study revealed that female (33 patients) have 15 months ofsurvival rate and mael (22 patients) have 18 months of survival rate. Breast was the most commonprimary location tumor (40%) and have highest survival rate (20 months). Cervix was the lowestsurvival rate (10 months) Overall patients who underwent surgical and chemotherapy have survivalrate in 17 months.